The Claim
Once-weekly subcutaneous retatrutide administration in adults with overweight, obesity, and/or type 2 diabetes over a period of 16 to 48 weeks is associated with a mean reduction of 10.66 kg in body weight, 4.53 kg/m² in BMI, and 6.61 cm in waist circumference, suggesting potential for clinically meaningful weight loss in this population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a weekly injection called retatrutide might help people who are overweight or have type 2 diabetes lose around 10-11 pounds, shrink their waistline, and lower their BMI — which could mean real, helpful weight loss.
See the scientific wording
Once-weekly subcutaneous retatrutide is associated with a mean reduction of 10.66 kg in body weight, 4.53 kg/m² in BMI, and 6.61 cm in waist circumference in adults with overweight, obesity, and/or type 2 diabetes over 16 to 48 weeks, suggesting potential for clinically meaningful weight loss in this population.
What the research says
1 studyThis study looked at a weekly shot called retatrutide in people with extra weight or diabetes and found that, on average, people lost about 10.7 kg, their BMI dropped by 4.5 points, and their waist got 6.6 cm smaller — exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.